Medizinisches Versorgungszentrum des Bruederkrankenhauses St. Josef Paderborn gGmbH — Clinical Trial Site

31 Registered trials

17 Currently recruiting

Organisation

Medizinisches Versorgungszentrum des Bruederkrankenhauses St. Josef Paderborn gGmbH

Location

Paderborn, Germany

Identifier

ORG-100040179

Address

Husener Strasse 46, Kernstadt, 33098, Germany

Departments

-
Clinic for Haematology and Oncology
Clinic for Haematology/Onkology
Department for hematology/oncology
Department of Hematology and Oncology
Hämatologie / Onkologie
Hämatologie Onkologie
Hämatologie/Onkologie
Hematology and Oncology
Hematology, Oncology
Klinik für Haematologie / Onkologie
Klinik für Hämatologie / Onkologie
Klinik für Hämatologie und Onkologie
Klinik für Hämatologie und Onkologie – Studienzentrum
Klinik für Hämatologie/ Onkologie
Klinik für Hämatologie/Onkologie
Klinik für Hämatolologie und Onkologie
Klinik für Strahlentherapie
not applicable

Clinical trials at this site (31)

Search interface

A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke… Pending

2024-514682-19-00 Resected pancreatic ductal adenocarcinoma 5
PREFer Recruiting

2024-520138-31-00 Early-stage favorable classic Hodgkin lymphoma 4 2026-06-01
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting

2023-509861-19-01 High-grade B-cell lymphoma (HGBL) 4 2025-09-30
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia Recruiting

2022-500574-34-00 Waldenström’s Macroglobulinemia 4 2025-03-21
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Recruiting

2022-500453-16-00 Multiple Myeloma 4 2023-10-30
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants Wi… Recruiting

2023-504599-10-00 Chronic lymphocytic leukemia recurrent 4 2022-03-29
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting

2024-514014-13-00 female and male adult patients with acute myeloid leuke 9 2020-09-02
A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBI-TOR, PLUS… Recruiting

2023-504653-12-00 Patients with previously untreated Richter Transformati 4 2020-02-10
Frontline Asciminib combination in chronic phase CML Ended

2024-516212-24-00 Chronic Myeloid Leukemia 4 2024-10-08
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended

2022-500571-32-00 Early-Stage Unfavorable Classical Hodgkin Lymphoma 4 2024-05-15
A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended

2022-502634-52-00 prostate cancer 5 2023-05-16
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Newly-diagnosed high-intermediate and high-risk diffuse 5 2021-04-23
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Waldenström’s Macroglobulinemia 4 2021-01-28